We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Eiger BioPharmaceuticals Inc (EIGR) USD0.0001

Sell:$5.17 Buy:$8.50 Change: $0.41 (6.54%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Change: $0.41 (6.54%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Change: $0.41 (6.54%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of drugs for serious diseases. Its lead clinical programs are focused on the development of treatments for Hepatitis Delta Virus (HDV), the severe form of viral hepatitis. Its clinical product candidates include Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, Avexitide in Post-Bariatric Hypoglycemia (PBH) and Avexitide in Congenital Hyperinsulinism (CHI). LNF is an orally bioavailable, farnesylation inhibitor in a Phase III clinical trial for HDV infection. Lambda is a late-stage, type III, interferon (IFN), that stimulates immune responses that are critical for the development of host protection during viral infections. Avexitide is a peptide, which is developing for the treatment for PBH. Avexitide is for the treatment of congenital hyperinsulinism (CHI), pediatric metabolic disorder.

Contact details

2155 Park Blvd
United States
+1 (650) 2799845

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$196.04 million
Shares in issue:
33.98 million
United States
US dollar

Key personnel

  • David Cory
    President, Chief Executive Officer, Director
  • Sriram Ryali
    Chief Financial Officer
  • Eldon Mayer
    Executive Vice President, Chief Commercial Officer
  • Erik Atkisson
    Chief Compliance Officer, General Counsel
  • James Shaffer
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.